Reverse line blot hybridization assay for identification of medically important fungi from culture and clinical specimens by Zeng, Xianyu et al.
JOURNAL OF CLINICAL MICROBIOLOGY, Sept. 2007, p. 2872–2880 Vol. 45, No. 9
0095-1137/07/$08.000 doi:10.1128/JCM.00687-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
Reverse Line Blot Hybridization Assay for Identification of Medically
Important Fungi from Culture and Clinical Specimens
Xianyu Zeng,1,2† Fanrong Kong,1† Catriona Halliday,1 Sharon Chen,1 Anna Lau,1
Geoffrey Playford,3,4 and Tania C. Sorrell1,3*
Centre for Infectious Diseases and Microbiology–Public Health (CIDM-PH), Institute of Clinical Pathology and Medical Research,
Westmead Hospital, Westmead, Australia1; Research Laboratory for Infectious Skin Diseases, Department of Dermatology,
Wuhan First Hospital, Wuhan, Hubei Province, People’s Republic of China2; Westmead Millennium Institute and
Department of Medicine, University of Sydney, Sydney, Australia3; and Infection Management Services,
Princess Alexandra Hospital, Brisbane, Australia4
Received 28 March 2007/Returned for modification 7 June 2007/Accepted 5 July 2007
We evaluated a combined panfungal PCR-reverse line blot (RLB) hybridization assay based on internal
transcribed spacer 1 (ITS1) and ITS2 region polymorphisms to identify 159 Candida, Cryptococcus neoformans,
and Aspergillus isolates (22 species). Its utility to identify fungal pathogens directly from 27 clinical specimens
was also determined. ITS sequence analysis was performed to resolve discrepant identifications or where no
RLB result was obtained. Species-specific ITS2- and ITS1-based probes correctly identified 155 of 159 isolates
(98%) and 149 (93.7%) isolates, respectively. All strains were unambiguously differentiated with the exception
of cross-reactivity between the Candida norvegensis probe and Candida haemulonii DNA product. Species
identification of the pathogen was made for all 21 specimens (sensitivity of 100%) where species-specific probes
were included in the RLB; however, there was no ITS2 probe-based hybridization signal for two specimens.
Results were concordant with the culture results for 18 (85.7%) specimens. The assay was able to provide
species identification in the absence of a culture result (two specimens) and to detect mixed infection (one
specimen). The results indicate that the RLB assay is capable of reliably detecting yeasts and Aspergillus spp.
in clinical specimens and that the incorporation of both ITS1- and ITS2-targeted probes is required for optimal
sensitivity. The test has potential utility in the early diagnosis of invasive fungal infection, since “fungal” DNA
was detected in all 27 specimens. Prior to incorporation of probes to detect other fungal species, ITS
sequencing may be performed to achieve species identification.
Invasive fungal infections (IFIs) are an important cause of
morbidity and mortality in severely ill and immunocompro-
mised patients. Recent epidemiological trends indicate a sig-
nificant shift towards species of Candida and Aspergillus other
than Candida albicans and Aspergillus fumigatus and a diverse
range of less common fungal opportunists (27, 29, 35). Given
the reduced susceptibility of many of these pathogens to stan-
dard antifungal agents (30, 35, 36), timely and accurate iden-
tification to the species level is essential in guiding clinical
management. Conventional culture-based phenotypic identifi-
cation methods, however, are slow and prone to misidentifica-
tion, particularly with less common or unusual species (20, 34).
In addition, the databases of commercial yeast identification
systems do not contain all potential pathogens (34).
Molecular approaches using PCR-based methods have been
developed to provide rapid and accurate detection of fungi. In
particular, the internal transcribed spacer (ITS) regions, ITS1
and ITS2, of the fungal ribosomal DNA gene complex, have
shown promise as targets for species identification in a variety
of formats, including DNA sequencing and DNA probe hy-
bridization (9, 13, 22). Both length and sequence polymor-
phisms within the ITS region have permitted accurate identi-
fication of pathogenic yeasts and molds (5–7, 12, 14, 22, 25, 33).
We previously developed a simple method to detect and iden-
tify Candida, Cryptococcus, and Aspergillus species using a pan-
fungal nested PCR followed by hybridization with species-
specific oligonucleotide probes targeting the ITS2 region in a
reverse line blot (RLB) assay (31).
For optimal sensitivity and specificity, combined analysis of
both ITS regions (ITS1 and ITS2) has been proposed (5, 22).
We have now designed and incorporated into the RLB assay
an additional set of probes targeting the ITS1 region and two
fungus-specific probes (targeting the 5.8S rRNA region). In the
present study, first we tested the ability of the new RLB assay
to identify 159 reference and clinical isolates representing 22
fungal species. We then evaluated the RLB assay on clinical
specimens obtained from patients with proven systemic myco-
ses to determine its utility in the early diagnosis of IFI. When
the species identification was ambiguous or differed from the
result obtained by culture-based methods (isolates and clinical
specimens) or when a culture result was not obtained (clinical
specimens), DNA sequence analysis of the ITS region was
performed to resolve the uncertainty.
MATERIALS AND METHODS
Fungal isolates and clinical specimens. Reference fungal strains were ob-
tained from the American Type Culture Collection (ATCC), the Centraalbureau
voor Schimmelcultures (CBS), the Australian Medical Mycology Reference Lab-
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TABLE 1. Species identification of fungal isolates studied by the RLB assay
Strain Species submitted as
Species identification by RLB with the following probe:
ITS1 ITS2
ATCC 90028 Candida albicans C. albicans C. albicans
CBS 562 C. albicans C. albicans C. albicans
WM01-157 C. albicans C. albicans C. albicans
WM01-158 C. albicans C. albicans C. albicans
WM01-159 C. albicans C. albicans C. albicans
WM01-160 C. albicans C. albicans C. albicans
WM01-161 C. albicans C. albicans C. albicans
WM01-162 C. albicans C. albicans C. albicans
WM01-163 C. albicans C. albicans C. albicans
WM01-217b C. albicans C. albicans C. albicans
WM01-217h C. albicans C. albicans C. albicans
WM01-218 C. albicans C. albicans C. albicans
CBS 7988 Candida dubliniensis C. dubliniensis C. dubliniensis
CBS 7987 C. dubliniensis C. dubliniensis C. dubliniensis
WM02-73 C. dubliniensis C. dubliniensis C. dubliniensis
WM03-78 C. dubliniensis C. dubliniensis C. dubliniensis
WM03-133 C. dubliniensis C. dubliniensis C. dubliniensis
WM03-160 C. dubliniensis C. dubliniensis C. dubliniensis
WM03-66 C. dubliniensis C. dubliniensis C. dubliniensis
WM03-79 C. dubliniensis C. dubliniensis C. dubliniensis
WM03-119 C. dubliniensis C. dubliniensis C. dubliniensis
WM01-54 C. dubliniensis C. dubliniensis C. dubliniensis
ATCC 90030 Candida glabrata C. glabrata C. glabrata
WM02-57 C. glabrata C. glabrata C. glabrata
WM02-174 C. glabrata C. glabrata C. glabrata
CBS 2030 Candida guilliermondii C. guilliermondii C. guilliermondii
CBS 2031 C. guilliermondii C. guilliermondii C. guilliermondii
CBS 5256 C. guilliermondii C. guilliermondii C. guilliermondii
WM02-72 C. guilliermondii C. guilliermondii C. guilliermondii
WM02-91 C. guilliermondii C. guilliermondii C. guilliermondii
WM02-131 C. guilliermondii C. guilliermondii C. guilliermondii
WM02-356 C. guilliermondii C. guilliermondii C. guilliermondii
WM02-374 C. guilliermondii C. guilliermondii C. guilliermondii
WM02-132 C. guilliermondii C. guilliermondii C. guilliermondii
WM02-361 C. guilliermondii C. guilliermondii C. guilliermondii
CBS 5149 Candida haemulonii C. haemulonii  C. norvegensis C. haemulonii  C. norvegensis
WM 889 C. haemulonii C. haemulonii  C. norvegensis C. haemulonii  C. norvegensis
WM 890 C. haemulonii C. haemulonii  C. norvegensis C. haemulonii  C. norvegensis
WM 891 C. haemulonii C. haemulonii  C. norvegensis C. haemulonii  C. norvegensis
CBS 834 Candida kefyr C. kefyr C. kefyr
CBS 712 C. kefyr C. kefyr C. kefyr
ATCC 4135 C. kefyr C. kefyr C. kefyr
WM 927 C. kefyr C. kefyr C. kefyr
ATCC 6258 Candida krusei C. krusei C. krusei
CBS 573 C. krusei C. krusei C. krusei
WM02-8 C. krusei C. krusei C. krusei
WM02-78 C. krusei C. krusei C. krusei
WM03-98 C. krusei C. krusei C. krusei
WM03-108 C. krusei C. krusei C. krusei
WM03-189 C. krusei C. krusei C. krusei
WM03-190 C. krusei C. krusei C. krusei
WM03-204 C. krusei C. krusei C. krusei
WM1057 C. krusei C. krusei C. krusei
WM1044 C. krusei C. krusei C. krusei
AS142 C. krusei C. krusei C. krusei
CBS 5094 Candida lusitaniae C. lusitaniae C. lusitaniae
CBS 5901 C. lusitaniae C. lusitaniae C. lusitaniae
CBS 4413 C. lusitaniae C. lusitaniae C. lusitaniae
CBS 6936 C. lusitaniae C. lusitaniae C. lusitaniae
WM02-92 C. lusitaniae C. lusitaniae C. lusitaniae
WM02-348 C. lusitaniae C. lusitaniae C. lusitaniae
WM02-9 C. lusitaniae C. lusitaniae C. lusitaniae
WM1036 C. lusitaniae C. lusitaniae C. lusitaniae
WM1037 C. lusitaniae C. lusitaniae C. lusitaniae
WM1038 C. lusitaniae C. lusitaniae C. lusitaniae
WM1074 C. lusitaniae C. lusitaniae C. lusitaniae
Continued on following page
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TABLE 1—Continued
Strain Species submitted as
Species identification by RLB with the following probe:
ITS1 ITS2
WM1138 C. lusitaniae C. lusitaniae C. lusitaniae
CBS 6403 Candida norvegensis C. norvegensis C. norvegensis
CBS 6564 C. norvegensis C. norvegensis C. norvegensis
CBS 4239 Candida norvegica C. norvegica C. norvegica
ATCC 22019 Candida parapsilosis C. parapsilosis C. parapsilosis
CBS 8501 C. parapsilosis C. parapsilosis C. parapsilosis
WM02-2 C. parapsilosis C. parapsilosis C. parapsilosis
WM02-61b C. parapsilosis C. parapsilosis C. parapsilosis
WM02-75 C. parapsilosis C. parapsilosis C. parapsilosis
WM02-89 C. parapsilosis C. parapsilosis C. parapsilosis
WM02-95 C. parapsilosis C. parapsilosis C. parapsilosis
WM02-130a C. parapsilosis C. parapsilosis C. parapsilosis
WM02-166 C. parapsilosis C. parapsilosis C. parapsilosis
WM02-177 C. parapsilosis C. parapsilosis C. parapsilosis
WM02-351 C. parapsilosis C. parapsilosis C. parapsilosis
WM2 359 C. parapsilosis C. parapsilosis C. parapsilosis
WM01-201 C. parapsilosis C. parapsilosis C. parapsilosis
WM01-219 C. parapsilosis C. parapsilosis C. parapsilosis
WM01-216 C. parapsilosis C. parapsilosis C. parapsilosis
CBS 605 Candida pelliculosa C. pelliculosa C. pelliculosa
WM 1039 C. pelliculosa C. pelliculosa C. pelliculosa
CBS 94 Candida tropicalis C. tropicalis C. tropicalis
WM01-202 C. tropicalis C. tropicalis C. tropicalis
WM01-203 C. tropicalis C. tropicalis C. tropicalis
WM01-215 C. tropicalis C. tropicalis C. tropicalis
WM02-86 C. tropicalis C. tropicalis C. tropicalis
WM02-87 C. tropicalis C. tropicalis C. tropicalis
WM02-181 C. tropicalis C. tropicalis C. tropicalis
WM02-183 C. tropicalis C. tropicalis C. tropicalis
WM02-355 C. tropicalis C. tropicalis C. tropicalis
WM1045 C. tropicalis C. tropicalis C. tropicalis
CBS 621 Candida utilis C. utilis C. utilis
CBS 1600 C. utilis C. utilis C. utilis
CBS 4024T Candida viswanathii C. viswanathii C. viswanathii
CBS 619 Candida zeylanoides C. zeylanoides C. zeylanoides
ATCC 204305 Aspergillus fumigatus A. fumigatus A. fumigatus
AS41 A. fumigatus A. fumigatus A. fumigatus
AS42 A. fumigatus A. fumigatus A. fumigatus
AS43 A. fumigatus A. fumigatus A. fumigatus
AS44 A. fumigatus A. fumigatus A. fumigatus
AS45 A. fumigatus A. fumigatus A. fumigatus
AS46 A. fumigatus A. fumigatus A. fumigatus
AS48 A. fumigatus A. fumigatus A. fumigatus
AS49 A. fumigatus A. fumigatus A. fumigatus
AS51 A. fumigatus A. fumigatus A. fumigatus
AS52 A. fumigatus A. fumigatus A. fumigatus
AS116 Aspergillus nidulans A. nidulans A. nidulans
AS60 A. nidulans A. nidulans A. nidulans
AS69 A. nidulans A. nidulans A. nidulans
AS128 A. nidulans A. nidulans A. nidulans
AS53 A. fumigatus A. fumigatus A. fumigatus
AS54 A. fumigatus A. fumigatus A. fumigatus
AS56 A. fumigatus A. fumigatus A. fumigatus
AS57 A. fumigatus A. fumigatus A. fumigatus
AS58 A. fumigatus A. fumigatus A. fumigatus
AS59 A. fumigatus A. fumigatus A. fumigatus
ATCC 204304 Aspergillus flavus A. flavus A. flavus
AS119 A. flavus A. flavus A. flavus
AS120 A. flavus A. flavus A. flavus
AS121 A. flavus A. flavus A. flavus
AS123 A. flavus A. flavus A. flavus
AS61 Aspergillus terreus A. terreus A. terreus
AS62 A. terreus A. terreus A. terreus
AS63 A. terreus A. terreus A. terreus
AS64 A. terreus A. terreus A. terreus
AS75 A. terreus A. terreus A. terreus
Continued on following page
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oratory at Royal North Shore Hospital, Sydney, Australia, and the Molecular
Mycology Research Laboratory at Westmead Hospital, Westmead, Australia.
Clinical isolates were obtained from the Mycology Laboratory at Westmead
Hospital. Isolates were identified using standard colonial and microscopic char-
acteristics (for molds) (20, 37) and the VITEK I (bioMerieux Vitek, Hazelwood,
MO) and/or ID 32C (bioMerieux, Marcy-l’Etoile, France) commercial systems
(for yeasts). Canavanine-glycine bromothymol blue (CGB) agar was used to
differentiate between Cryptococcus neoformans (Cryptococcus neoformans var.
neoformans and Cryptococcus neoformans var. grubii) and Cryptococcus gattii (19).
A total of 159 (32 reference and 127 clinical) isolates belonging to 22 fungal
species were studied; all species were represented by species-specific probes in
the RLB assay (Table 1). Isolates comprised 16 Candida species (101 strains;
Candida albicans, Candida dubliniensis, Candida glabrata, Candida guilliermondii,
Candida haemulonii, Candida kefyr, Candida krusei, Candida lusitaniae, Candida
norvegica, Candida norvegensis, Candida parapsilosis, Candida pelliculosa, Can-
dida tropicalis, Candida utilis, Candida viswanathii, Candida zeylanoides), C. neo-
formans complex (five strains of C. neoformans var. grubii, four strains of C.
neoformans var. neoformans, and eight strains of C. gattii), and five Aspergillus
species (40 strains; Aspergillus fumigatus, Aspergillus flavus, Aspergillus niger,
Aspergillus terreus, and Aspergillus nidulans).
Twenty-seven clinical specimens from 24 patients with proven IFI were eval-
uated (Table 2). Specimens included fresh tissue (n  13), formalin-fixed par-
affin-embedded (PE) tissue (n  7), anticoagulated whole blood (n  4), bron-
choalveolar lavage (BAL; n  2) fluid, and cerebrospinal fluid (CSF; n  1)
samples.
DNA extraction. For fungal isolates, DNA extraction was performed as pre-
viously described (31). For clinical specimens, DNA extractions were performed
using the MagNA Pure LC instrument (Roche Diagnostics, Mannheim, Ger-
many) in a class II laminar flow cabinet as outlined below.
(i) Blood, BAL fluid, and CSF specimens. The MagNA Pure LC total nucleic
acid isolation kit (Roche Diagnostics) was used for extraction of blood, BAL, and
CSF specimens with some modifications. Blood samples (500 l) were lysed with
erythrocyte lysis buffer and incubated with sorbitol buffer and lyticase as outlined
previously (11). BAL (600-l) and CSF (100- to 200-l) samples were centri-
fuged at 16,100  g for 10 min, and the pellet was resuspended in 200 l of
sorbitol buffer (1 M sorbitol, 100 mM EDTA, and 0.1% 2-mercaptoethanol) (38)
and 200 U lyticase (Sigma-Aldrich, Castle Hill, Australia). After incubation at
37°C for 60 min, the spheroplasts were precipitated by centrifugation at 5,400 
g for 5 min. The supernatant was discarded, and the pellet was resuspended in
200 l of distilled H2O before being transferred to the MagNA Pure sample
cartridge for processing on the MagNA Pure LC instrument (Roche Diag-
nostics).
(ii) Fresh and PE tissue specimens. The MagNA Pure LC DNA isolation kit
II (tissue) (Roche Diagnostics) was used to extract DNA from fresh and PE
tissue specimens as previously described (21).
Oligonucleotide design. Relevant fungal DNA sequences spanning the fungal
ribosomal DNA gene complex (18S, 5.8S, and 28S) and the intervening ITS1 and
ITS2 regions were accessed from GenBank and compared using the Pileup and
Pretty programs provided by BioManager, ANGIS (http://biomanager.angis.org
.au/). Three pairs of panfungal primers amplifying the ITS1 (its1Sb and its2Ab),
ITS2 (its3Sb and its4Ab), and ITS1, 5.8S, and ITS2 regions (SR6RL/LR1L)
(Table 3) were designed from the multiple-sequence alignment. All primers were
5-end biotin labeled (Sigma-Aldrich). Two panfungal oligonucleotide probes
(its12Ap and its23Sp) were designed to target the 5.8S rRNA region (Table 3).
Species-specific fungal probes targeted the ITS1 or ITS2 region. The ITS2 probes
have been described previously (31). The ITS1 probes were either modified from
published probe sequences (28) or designed de novo (Table 3). All oligonucle-
otide probes were 5-hexylamine labeled (Sigma-Aldrich).
Multiplex PCR and nested PCR. (i) Fungal isolates. Multiplex PCR using the
primer pairs, its1Sb/its2Ab and its3Sb/its4Ab, was performed to amplify the ITS1
and ITS2 regions. PCRs were performed in 25-l reaction mixtures containing
0.5 U HotStar Taq polymerase and 1 PCR buffer (catalogue no. 203203;
QIAGEN, Doncaster, Victoria, Australia), 125 M of each dATP, dCTP, dGTP,
and dTTP (Roche Diagnostics), 0.5 M of each forward and reverse primer, and
5 l of DNA template. Amplification was performed on a Mastercycler gradient
thermocycler (Eppendorf AG, North Ryde, Australia). The thermal cycling con-
ditions were 95°C for 15 min, followed by 35 cycles of 94°C for 30 s, 55°C for 30 s,
and 72°C for 60 s, with a final extension step at 72°C for 10 min.
(ii) Clinical specimens. A nested PCR assay was used as follows: the first-
round PCR targeted the ITS1, 5.8S, and ITS2 regions using the primer pair
SR6RL/LR1L, and the second-round PCR amplified the ITS1 or ITS2 region
using primer pairs its1Sb/its2Ab and its3Sb/its4Ab, respectively. The first-round
TABLE 1—Continued
Strain Species submitted as
Species identification by RLB with the following probe:
ITS1 ITS2
AS7 Aspergillus niger NSa A. niger
AS31 A. niger NS A. niger
AS32 A. niger A. niger A. niger
AS33 A. niger NS A. niger
AS35 A. niger A. niger A. niger
AS36 A. niger NS A. niger
AS37 A. niger NS A. niger
AS38 A. niger A. niger A. niger
AS39 A. niger NS A. niger
RV 58146 Cryptococcus neoformans var.
neoformans
C. neoformans complex C. neoformans complex
JG 02 C. neoformans var. neoformans C. neoformans complex C. neoformans complex
RV 58146 C. neoformans var. neoformans C. neoformans complex C. neoformans complex
PR 101 C. neoformans var. neoformans C. neoformans complex C. neoformans complex
CDCR 461 Cryptococcus neoformans var. grubii C. neoformans complex C. neoformans complex
KRIMM 2 C. neoformans var. grubii C. neoformans complex C. neoformans complex
CBS 7816 C. neoformans var. grubii C. neoformans complex C. neoformans complex
WM01-84 C. neoformans var. grubii C. neoformans complex C. neoformans complex
WM01-85 C. neoformans var. grubii C. neoformans complex C. neoformans complex
WM148 C. neoformans var. grubii C. neoformans complex C. neoformans complex
WM179 Cryptococcus gattii C. neoformans complex C. neoformans complex
4A C. gattii C. neoformans complex C. neoformans complex
4B C. gattii C. neoformans complex C. neoformans complex
4C C. gattii C. neoformans complex C. neoformans complex
10A C. gattii C. neoformans complex C. neoformans complex
10B C. gattii C. neoformans complex C. neoformans complex
10B C. gattii C. neoformans complex C. neoformans complex
10C C. gattii C. neoformans complex C. neoformans complex
a Abbreviation: NS, hybridized only with fungus-specific probes and no hybridization signal with species-specific probes.
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PCR mixture (25 l) consisted of 1 PCR buffer 1 (0 mM Tris-HCl [pH 8.3], 50
mM KCl, 1.5 mM MgCl2, and 0.001% gelatin) (Applied Biosystems, Foster City,
CA), 5% glycerol (Sigma-Aldrich), 25 M each dATP, dCTP, dGTP, and dTTP,
0.5 M of each forward and reverse primer, 1.25 U of AmpliTaq Gold DNA
polymerase, and 10 l DNA template. The thermal cycling conditions were 95°C
for 10 min, followed by 30 cycles of 94°C for 15 s, 55°C for 30 s, and 72°C for 90 s,
and a final extension at 72°C for 6 min. Conditions for the second-round PCR
were identical, except that 2 l of template was used and the amplification
involved 35 cycles.
RLB hybridization assay. The RLB assay was performed as previously de-
scribed (18, 31). Briefly, the amplified PCR product was hybridized with mem-
brane-bound probes at 60°C for 1 h, the membrane was washed twice (10 min
each time) at 60°C with prewarmed (to 60°C) 2 SSPE (1 SSPE is 0.18 M
NaCl, 10 mM NaH2PO4, and 1 mM EDTA [pH 7.7])-0.5% sodium dodecyl
sulfate (SDS) and incubated in 15 ml of streptavidin-peroxidase conjugate
(Roche Diagnostics) diluted 1:4,000 in 2 SSPE-0.5% SDS for 60 min at 42°C.
The membrane was further washed with 2 SSPE-0.5% SDS at 42°C and then
at 25°C. If present, bound PCR products were detected by chemiluminescence
using ECL detection liquid (Amersham) and visualized by exposure for 7 min to
an X-ray film (Hyperfilm; Amersham).
ITS sequencing. ITS sequence analysis was performed for fungal strains and
clinical specimens which yielded either a discrepant (compared to culture) or
ambiguous species identification result or when no hybridization signal was
obtained by the RLB assay. For fungal strains, the ITS1, 5.8S, and ITS2 regions
were amplified using the SR6RL and LR1L primer pair as described for multi-
plex PCR (see above). For clinical specimens, parameters used for PCR were
identical to those used for the RLB assay except that in the second amplification,
either the primer pair its1Sb/its2Ab or its3Sb/its4Ab was used. Both the ITS1 and
ITS2 regions were amplified and analyzed. PCR products were purified using the
PCR Product Pre-sequencing kit (USB Corporation, Cleveland, OH) and were
sequenced using forward primer and the BigDye Terminator (version 3.1) cycle
sequencing kit in the ABI PRISM 3100 genetic analyzer (Applied Biosystems).
Sequences were entered into a BLASTn sequence analysis search (2) (accessed
via http://biomanager.angis.org.au/).
RESULTS
Fungal isolates. The universal fungal primers SR6RL and
LR1L amplified the ITS1, 5.8S, and ITS2 regions for all 159
isolates. Species-specific ITS2 probes correctly identified 155
(98%) isolates by the RLB assay; the corresponding ITS1
probes identified 149 of 159 (93.7%) strains (Table 1). With
one exception (see below), the ITS1- and ITS2-specific RLB
assays clearly identified major Candida species, including C.
zeylanoides and C. guilliermondii (Table 1). The assays did not
differentiate between members of the C. neoformans complex.
RLB assay results, using both ITS1 and ITS2 species-specific
probes, correlated with culture identification for 149 of 159
(93.7%) strains. Isolates that produced inconsistent results or
no hybridization signal are listed in Table 4. Four C. haemu-
lonii strains hybridized with both (ITS1 and ITS2) C. haemu-
lonii-specific and C. norvegensis-specific probes; in all instances,
ITS sequence analysis yielded sequences with 100% identity to
C. haemulonii sequences in the GenBank database. In the ITS
regions employed for probe design, C. haemulonii- and C.
norvegensis-specific sequences had sequence identities of 35%
and 55% for the ITS1 and ITS2 region, respectively. The other
discrepant results involved six of the nine A. niger strains (AS7,
TABLE 2. Results of culture, histology, RLB, and ITS sequence analysis of clinical specimens from patients with proven IFI
Patient
no. Specimen type Clinical diagnosis
a Identification by
culture/histology
Molecular identification by:
RLB
ITS1 sequencing
(% identity with
GenBank sequence)
ITS2 sequencing
(% identity with
GenBank sequence)
1 Blood Candidemia Candida albicans C. albicans
2 Blood Candidemia C. albicans C. albicans
3 Blood Candidemia C. albicans C. albicansb C. albicans (99) No result
4 CSF IC C. albicans C. albicans
5 Tissue (vocal cord) IC C. albicans C. albicans
6 Blood Candidemia Candida parapsilosis C. parapsilosis
7 Tissue (bladder) IC Candida krusei C. krusei
8 Tissue (skin) IC Candida glabrata C. glabrata
9 BAL Cryptococcosis Cryptococcus neoformans C. neoformans complexc
10 BAL Cryptococcosis C. neoformans C. neoformans complex
11 Tissue (nasal mucosa) Cryptococcosis C. neoformans C. neoformans complex
12 PE tissue (nasal cavity) Cryptococcosis C. neoformans C. neoformans complexb C. neoformans complex
(99)
No result
13 Tissue (lung) Cryptococcosis C. neoformans C. neoformans complex
14 PE tissue (skin) Cryptococcosis C. gattii C. neoformans complex
15 Tissue (lung) IA Aspergillus fumigatus A. fumigatus
16 Tissue (nasal cavity) IA A. fumigatus A. fumigatus
17 PE tissue (nasal cavity) IA A. fumigatus A. fumigatus
18 Tissue (sinus) IFI Filamentous fungus A. fumigatus
PE tissue (sinus) IFI Filamentous fungus A. fumigatus
19 Tissue (nasal mucosa) IA A. fumigatus A. fumigatus  A. flavusd A. fumigatus (100) A. fumigatus (100)
20 Tissue (sinus) IA Aspergillus flavus A. flavus
21 Tissue (skin) Dematiaceous IFI Exophiala jeanselmei NSe Exophiala spinifera No result
22 Tissue (buttock) Zygomycosis Apophysomyces elegans NS A. elegans (100)f Not performed
Tissue (buttock) Zygomycosis A. elegans NS A. elegans (96) No result
23 PE tissue (lung) Zygomycosis Filamentous fungus NS Rhizopus microsporus (99)f Not performed
24 PE tissue (pericardium) IFI Fungal hyphae NS Trichosporon asahii (100)f Not performed
PE tissue (kidney) IFI Fungal hyphae NS T. asahii (99)f Not performed
a Abbreviations: IA, invasive aspergillosis; IC, invasive candidiasis.
b Hybridized with the species-specific ITS1 probe only.
c The assays did not differentiate between members of the C. neoformans complex; however, if necessary, the known limited diversity in the ITS region would be useful
in differentiating between species and varieties of C. neoformans.
d Hybridized with both (ITS1 and ITS2) A. fumigatus-specific probes and with both (ITS1 and ITS2) A. flavus-specific probes.
e NS, hybridization with fungus-specific probes but not with species-specific probes.
f As published by Lau et al. (21).
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AS31, AS33, AS36, AS37, and AS39) studied. These isolates
hybridized with the ITS2, but not the ITS1, A. niger-specific
probe (Table 4). Sequence analysis of the ITS1 region for all
six strains demonstrated 100% identity to A. niger ATCC 16888
sequence (GenBank accession no. AY373852); this sequence
showed a single base polymorphism (from A to G) with the
GenBank sequence used to design the ITS1-based probe
(GenBank accession no. AY213633).
Clinical specimens. The RLB assay detected fungal DNA in
all 27 specimens using the panfungal probe. The identification
of the fungal pathogen, as determined by phenotypic-based
methods, RLB, and/or ITS sequence analysis are summarized
in Table 2. RLB analysis assigned a species identification for all
21 specimens for which species-specific probes were available.
The sensitivities of the assay with the ITS1- and ITS2-based
probes were 100% (21 of 21) and 90.5% (19 of 21), respec-
tively. Hybridization occurred with both probes for all but two
specimens (patients 3 and 12) where a hybridization signal was
observed only with the ITS1 probe.
Concordant results with culture were obtained for 18 of 21
(85.7%) specimens using both ITS1 and ITS2 species-specific
probes. For two specimens (from patient 18), RLB provided a
species identification in the absence of a culture result. For the
remaining specimen (nasal mucosa; patient 19), A. fumigatus
was recovered on culture but both A. fumigatus and A. flavus
DNA were detected by RLB (Table 2). ITS sequence analysis
detected A. fumigatus DNA only (100% sequence identity to A.
fumigatus sequences in GenBank accession no. AY939790).
Examination of A. fumigatus- and A. flavus-specific ITS se-
quences in the region targeted by the probes revealed they
were dissimilar.
No hybridization signal was observed for six specimens (pa-
tients 21 to 24; Table 2). In these instances, ITS1 and ITS2
sequencing identified the pathogen to be a fungus not repre-
sented by probes on the RLB (as described previously for
specimens from patients 23 and 24 [21] and in this study for
specimens from patients 21 and 22). The molecular identifica-
tion was consistent with culture and/or histological diagnosis
for five of six (83.3%) specimens. The single discrepancy in-
volved a skin biopsy specimen (patient 21) where culture-based
methods identified the pathogen as Exophiala jeanselmei but
sequencing revealed results with 99% identity to Exophiala
TABLE 3. Primers and oligonucleotide probes used in this study
Primer or
probe Target Tm (
oC)a GenBankaccession no. Sequence (5 to 3)
b
Primers
its1Sb 18S 68.4 AF455524 19TCCGTAGGGAACCTGCGG37
its12Ap 5.8S 64.6 AF455524 211CCAAGAGATCCGTTGTTGAAAG190
its2Ab 5.8S 69.1 AF455524 237CGCTGCGYTCTTCATCGATG208
its3Sb 5.8S 62.0 AF455524 242GCGATAMGTAATRTGAATTGCAG264
its23Sp 5.8S 64.3 AF455524 271GTGAATCATCGARTCTTTGAACG293
its4Ab 28S 72.9 L28817 741GTTGGTTTCTTTTCCTCCGCTTAT TGATATGC710
SR6RL 18S 73.5 DQ157694 529CAAACYYGGTCAYTTAGAGGAAGWAAAAGTCG
TAACAAGG568
LR1L 28S 74.6 DQ139803 46CTRRGGCAATCCCDGTTGGTTTCTTTTCCT17
Probes
CA ITS1 of C. albicans 68.4 AF455524 149TTTATCAACTTGTCACACCAGA170
CD ITS1 of C. dubliniensis 67.3 AJ249485 51ACATGTGTTTTGTTYTGGACAAACTTG77
CG ITS1 of C. glabrata 68.2 AF455515 22TGTCTGAGCTCGGAGAGAGACATC45
CGU ITS1 of C. guilliermondii 67.0 AB105435 107GCTTTGGTTTGGCCTAGAGATAGGT131
CH ITS1 of C. haemulonii 62.4 AY500375 64GCAACCACCGTTAAGTTCAA83
CKF ITS1 of C. kefyr 66.5 AY046214 118GAGTTTTCYCTATGAACTACTTCCCTGG147
CKR ITS1 of C. krusei 64.8 AB054034 95TGTGGAATATAGCATATAGTCGACAAGAG123
CLUS ITS1 of C. lusitaniae 62.6 AY493434 299TGTCAAACACGTTTACAGCACG320
CNOV ITS1 of C. norvegica 64.6 AY936525 55TATGCGAGATTGCTTTGGCT74
CNS1 ITS1 of C. norvegensis 70.4 AY939799 58CGTGAGCGCACAACAACAC77
CNS2 ITS2 of C. norvegensis 69.6 AY939799 406GGCCCGCCGAACTTTTTTTT425
CP ITS1 of C. parapsilosis 65.1 AF455530 148CTGCCAGAGATTAAACTCAACCAA171
CPL ITS1 of C. pelliculosa 65.21 AF270936 118YGCCCAAAGGTCTAAACACATTT140
CT ITS1 of C. tropicalis 64.5 AF287910 121CTACCGCCAGAGGTTATAACTAAACC146
CU ITS1 of C. utilis 68.5 AF335929 57CGGCTCCAACCAATACACAGTG78
CV ITS1 of C. viswanathii 69.9 AY139791 57GTTTTTTACTGGACAGCTGCTTTGGC82
CZ ITS1 of C. zeylanoides 66.7 AF335930 110GGTCTGACTTAGAAATGAGTTGGGC134
CRY ITS1 of Cryptococcus
neoformans complex
64.5 AJ493561 64TTCGGCACGTTTTACACAAAC84
AFL ITS1 of A. flavus 67.1 AY373848 174TCTAGTGAAGTCTGAGTTGATTGTATCGC202
AFUM ITS1 of A. fumigatus 64.5 AY373851 181GTATGCAGTCTGAGTTGATTATCGTAATC209
ANID ITS1 of A. nidulans 70.1 AY452983 161CTTCATGCCTGAGAGTGATGCAGTC185
ANIG ITS1 of A. niger 63.4 AY213633 65CGTGTCTATTATACCCTGTTGCTTC89
ATER ITS1 of A. terreus 68.9 AY373871 182CTTGCAGTCTGAGTGTGATTCTTTGC207
a Tm, melting temperature.
b Boldface numbers represent the numbered base positions where the primer or probe sequences start or finish (starting at point 1 of the corresponding gene
GenBank sequence). Underlined sequences show bases added to modify previously published probes and primers (28).
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spinifera (88 to 92% identity to E. jeanselmei; GenBank acces-
sion no. AY163550 and AY163556, respectively).
DISCUSSION
This study demonstrates the feasibility of combining a pan-
fungal nested PCR with probe hybridization technology in a
RLB format to identify clinically important fungal pathogens.
Important features of this RLB assay, which incorporates both
ITS1- and ITS2-targeted probes, include the high sensitivity
(98%) for the identification of 22 fungal species and the ability
to identify fungal pathogens directly from clinical specimens.
The validity of the RLB assay was confirmed by analysis of a
large number of the more common pathogenic yeasts and
Aspergillus species. With one exception, major Candida spp.
were unambiguously differentiated. The cross-reactivity be-
tween the C. norvegensis probe and C. haemulonii DNA prod-
uct is unexplained, as multiple GenBank database ITS se-
quences in the region employed for probe design between
these species are dissimilar. In contrast to previous observa-
tions, C. guilliermondi was differentiated from C. zeylanoides
(28, 31). Both C. neoformans probes (CNEO [31] and CRY
[Table 3]) were designed on conserved sequences and thus
hybridized with all members of C. neoformans complex. Like-
wise, previous ITS-based analyses have not provided species
identification within C. neoformans (7, 15, 22); however, a
more recent study found diversity in the ITS region to be useful
in differentiating between species and varieties of C. neofor-
mans (17). If required, the RLB used in our study can be
modified to incorporate probes specific for these species/vari-
eties.
Incorporation of both ITS1 and ITS2 probes into the assay
enabled major Aspergillus spp. to be identified. The ability of
the current assay to distinguish between members of the A.
fumigatus clade (e.g., Neosartorya fischeri, Aspergillus lentus)
was not tested. This distinction is clinically relevant, as A.
lentulus and Neosartorya spp. have been reported to be less
susceptible in vitro to antifungal agents (3). Previous analyses
reveal little difference between the ITS sequences of these
closely related species (3, 21), suggesting that probes based on
alternative gene targets (e.g., the -tubulin and rodlet A genes)
would be required (3).
The results from this study support the notion that the use of
both ITS loci for fungal identification provides more informa-
tive data than that of either locus alone (5, 7). For fungal
isolates, ITS2 sequence polymorphisms were more species spe-
cific than their ITS1 counterpart; for example, in A. niger,
intraspecies ITS1 sequence divergence was higher than in the
ITS2 region (Table 4). This has implications for study of po-
tential subtypes of A. niger and other Aspergillus spp. Con-
versely, DNA amplified from two clinical specimens hybridized
with only the ITS1 probe (patients 3 and 12, Table 2). When
these same specimens were subjected to ITS sequence analysis,
only the ITS1 (and not ITS2) region was amplified. Similarly,
for specimens from patients 21 and 22, DNA sequence analysis
was successful for the ITS1, but not the ITS2, region. The
reasons for these results are not readily explained. Failure of
the ITS2 probe to hybridize to the DNA is unlikely to be due
to degradation of fungal DNA, as the ITS1 region was success-
fully amplified and analyzed. Others have reported yeast iden-
tification rates of 96.8% and 99.7% based on ITS1 and ITS2
sequencing, respectively, of fungal cultures (22). The relative
utility of ITS1 and ITS2 loci in determining species identifica-
tion and phylogenetic relationships is the subject of ongoing
study.
We successfully applied the RLB assay to identify Candida,
Aspergillus, and Cryptococcus spp. in clinical specimens, includ-
ing blood and PE tissue samples, with high (100% for ITS1-
based probes and 90.5% for ITS2-based probes) sensitivity. In
particular, the assay was able to provide a diagnosis in the
absence of a culture result (patient 18) and was capable of
diagnosing possible mixed infection (patient 19). Furthermore,
the results indicate that the RLB has potential utility in the
early diagnosis of IFI, as it detected the presence of a “fungal
pathogen” in all cases of IFI caused by species not represented
by probes on the RLB. In one instance (patient 21, Table 2),
the pathogen was finally determined to be E. spinifera by
TABLE 4. List of isolates that produced ambiguous species identification or that were not identified by the RLB assay
Strain Species received as
Species identification by:
RLB with ITS1 probe RLB with ITS2 probe ITS sequencing (% identitywith GenBank sequences)
Reference strains
CBS 5149 Candida haemulonii C. haemulonii  C. norvegensis C. haemulonii  C. norvegensis C. haemulonii (100)b
WM 889 C. haemulonii C. haemulonii  C. norvegensis C. haemulonii  C. norvegensis C. haemulonii (100)b
WM 890 C. haemulonii C. haemulonii  C. norvegensis C. haemulonii  C. norvegensis C. haemulonii (100)b
WM 891 C. haemulonii C. haemulonii  C. norvegensis C. haemulonii  C. norvegensis C. haemulonii (100)b
Clinical isolates
AS7 Aspergillus niger NSa A. niger A. nigerc
AS31 A. niger NS A. niger A. nigerc
AS33 A. niger NS A. niger A. nigerc
AS36 A. niger NS A. niger A. nigerc
AS37 A. niger NS A. niger A. nigerc
AS39 A. niger NS A. niger A. nigerc
a Abbreviation: NS, hybridization with fungus-specific probes but not with species-specific probes.
b Sequence analysis yielded sequences with 100% identity to C. haemulonii sequences in GenBank (accession nos. AY50035 and AJ606467).
c Sequence analysis yielded sequences with 100% identity to A. niger ATCC 16888 sequence (GenBank accession no. AY373852) but with a single base polymorphism
(from A to G) with the GenBank sequence used to design the probe (GenBank accession no. AY213633).
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ITS sequence analysis but identified morphologically as E.
jeanselmei. Comparison of GenBank ITS sequences of both
these species revealed the two can be easily distinguished (20).
Identification of Exophiala spp. is problematic due to variable
morphological characteristics within this genus (14, 32). It is
likely the culture-based identification was incorrect.
While probe hybridization technology has been successfully
used for identification of fungal isolates (1, 2, 8, 23, 24), species
identification from clinical specimens has remained a chal-
lenge. Real-time PCR systems have been developed to meet
these demands but are limited by false-negative and false-
positive results inherent in PCR and the number of fungal
species that can be simultaneously identified (4, 16, 26). We
chose a simple nested PCR-RLB format as an alternative to
culture for fungal identification given the advantages of low
cost, inherent high sensitivity, good specificity (10; this study),
and the capacity to simultaneously analyze multiple strains
against multiple probes (10). Although only 22 probes (two
probes per species) were used in this study, up to 43 may be
incorporated (one probe per species), extending the range of
pathogens that can be identified. This flexibility and versatility
also allow laboratories to readily modify or “customize” the
RLB format to meet specific requirements or for use in a
particular clinical setting. For example, in the rapid diagnosis
of fungemia, species-specific probes representative of causative
agents of fungemia other than Candida spp., e.g., Scedospo-
rium prolificans, may be included.
The identification of uncommon but emerging fungal patho-
gens continues to pose a challenge. Based on the results of this
study, for suspected Candida, Cryptococcus, or Aspergillus iso-
lates, the RLB assay is a reliable alternative to conventional
identification methods, especially if there is a need to identify
more than one isolate at the same time. Notably, the assay
performed well when applied to clinical specimens. We envis-
age it will be most useful if culture-based identification is not
made or when clinical specimens fail to be submitted for cul-
ture, as can occur following surgery. In the event a “fungus” is
detected on RLB but not identified further due to lack of
inclusion of the species-specific probe in the assay, the more
expensive and time-consuming ITS sequencing can be per-
formed. ITS sequence analysis to identify fungal pathogens
directly from tissue specimens has been successfully imple-
mented in our laboratory, but the turnaround time is signifi-
cantly increased relative to RLB by our outsourcing of the
DNA sequencing (21). Evaluation of larger numbers of spec-
imens is required to position the RLB assay and/or DNA
sequence analysis within routine diagnostic algorithms.
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